Business
Veeva and H&E Equipment Services have been highlighted as Zacks Bull and Bear of the Day
Veeva and H&E Equipment Services have been highlighted as Zacks Bull and Bear of the Day
About this update from Coca-cola Femsa Sab De Cv Units Cons Of 5 Shs -l- + 3 Shs Series -b-
For Immediate ReleaseChicago, IL – May 13, 2024 – Zacks Equity Research shares Veeva Systems VEEV as the Bull of the Day and H&E Equipment Services, Inc. HEES as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Constellation Brands Inc. STZ, PepsiCo, Inc. PEP and Coca-Cola FEMSA KOF.Here is a synopsis of all five stocks.Bull of the Day:Veeva Systems is a cloud software stock ripe for a breakout after chopping around the last few years as the wider tech sector and the Nasdaq soared to all-time highs.Veeva’s various cloud software offerings serve vital segments of the economy from pharmaceutical giants to biotech upstarts. VEEV’s earnings outlook has improved significantly and its balance sheet is outstanding—$4 billion in cash and equivalents and $5.91 billion in total assets vs. $1.27 in total liabilities, with zero debt.Veeva grew its sales from $210 million in FY14 to $2.36 billion last year, helping boost VEEV shares by 960% over the last decade to triple the Zacks Tech sector. Yet, VEEV trades roughly 40% below its peaks and 17% under its average Zacks price target.The tech firm and the stock are proven winners. Now might be the time for investors to heed tried-and-true investment advice and buy Veeva while others are fearful.Essential Tech for BiotechsVeeva sells cloud-based offerings geared toward the pharmaceutical and life sciences industries. Some of the largest biopharmaceuticals in the world, including firms like Merck, Bayer, Bristol Myers Squibb, and beyond utilize an array of Veeva’s offerings.Veeva helps clients improve and streamline their critical business functions, with software and services for research and development, regulatory processes and compliance, safety, clinical trials, marketing, and beyond.Veeva’s technology enables its clients to bring “products to market faster and more efficiently” while maintaining compliance. Veeva closed 2023 (its fiscal 2024) with 1,432 customers, adding 44 from the prior year. Veeva’s R&D Solutions segment boasted 1,078 customers and Commercial Solutions finished last year with nearly 700 customers.Veeva is one of the only tech firms that joins together clinical operations and clinical data management. Veeva’s Clinical Platform enables its customers to connect sponsors, research sites, and patients for more effective and efficient clinical trials.VEEV has also rolled out...